PharVision Advisers’s Avita Medical RCEL Stock Holding History

PharVision Advisers’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,508	Closed	-$87.3K	–	768
2025 Q2	$87.3K	Buy	+16,508	New	+$120K	0.13%	257

Other funds holding RCEL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

PharVision Advisers's RCEL Position: Q3 2025 in Review

PharVision Advisers sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 16,508 shares — an estimated $87.3K sold.

PharVision Advisers first reported a position in RCEL in Q2 2025 and held it in 1 quarter. The position peaked at $87.3K in Q2 2025. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

PharVision Advisers reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 16,508 Avita Medical shares in Q3 2025, an estimated $87.3K.
PharVision Advisers first reported a position in Avita Medical in Q2 2025 and held it in 1 quarter.
PharVision Advisers's Avita Medical position peaked at $87.3K in Q2 2025.
76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.